We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Parkinson’s Disease Patients at Higher Risk for Melanoma

By LabMedica International staff writers
Posted on 24 Jul 2017
Study finds that people with Parkinson’s disease have a much higher risk of the skin cancer melanoma, and vice versa. More...
Physicians treating patients with one disease should be vigilant for signs of the other in order to achieve early diagnosis and treatment, and patients should be educated about the risk of developing the other illness.

Medical experts have speculated about causes underlying the connection between Parkinson’s and melanoma for decades, with varying conclusions. Several studies have suggested levodopa, a drug for Parkinson’s, may be implicated in malignant melanoma, but others have found an association between the two diseases regardless of levodopa treatment.

According to a Mayo Clinic (Rochester, MN, USA) study led by Jose Pulido, MD: patients with Parkinson’s were roughly 4 times likelier to have had a history of melanoma than those without Parkinson’s, and patients with melanoma had a 4-fold higher risk of developing Parkinson’s. The study team used the Rochester Epidemiology Project medical records database to identify all neurologist-confirmed Parkinson’s cases from January 1976 through December 2013 among Olmsted County (MN, USA) residents. They examined the prevalence of melanoma in those 974 patients compared with 2,922 residents without Parkinson’s. They also identified 1,544 cases of melanoma over that period and determined the 35-year risk of Parkinson’s in those patients compared with the risk in people without melanoma.

The results support an association between Parkinson’s disease and melanoma, but argue against levodopa as the cause. It is likelier that common abnormalities underlie both conditions in patients who have both, but more research is needed to confirm that and refine screening recommendations.

“Future research should focus on identifying common genes, immune responses, and environmental exposures that may link these two diseases,” said first author Lauren Dalvin, MD, a Mayo Foundation scholar, “If we can pinpoint the cause of the association between Parkinson’s disease and melanoma, we will be better able to counsel patients and families about their risk of developing one disease in the setting of the other."

The study, by Dalvin LA et al, was published July 2017 in the journal Mayo Clinic Proceedings.

Related Links:
Mayo Clinic


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.